



Medication Safety Series: MSS 18

Safe Transfer of Psychotropic Medication at Discharge from Inpatient Wards

- Where psychotropic medication is unchanged (drugs & doses) from admission, it is suitable for immediate transfer to the GP; a minimum 7 day supply should be provided on discharge & the GP requested to continue prescribing.
- Where psychotropic medication is initiated or amended (drug and/or dose) during admission, or shortly prior to admission (e.g. by crisis team), it is important to ensure it is transferred in a timely manner to the most appropriate community prescriber. In these cases:
 - Patients should be issued with a 28 day supply of any newly initiated or amended psychotropic medication unless:
 - prescribed clozapine (quantity determined by the blood result & next clinic appointment)
 - suicidality or another risk with > 7 days' supply of medication is present. (see below)
- ➤ Where the patient uses a monitored dosage system or requires 7 day supplies:
 - Extra care needs to be taken during the transfer process. The in-patient team should discuss with GP, CMHT and community pharmacy, the most appropriate route of supply to maximise patient safety. This should be part of the discharge planning meeting.
 - o Options may include CMHTs holding 3x7 days instalments, post-dated prescriptions or collection from Trust pharmacy, until arrangements can be actioned with primary care.
- The **RAG status** within the "Safe Transfer of Prescribing Guidance" of the newly initiated or amended psychotropic **drug determines the most appropriate community prescriber** for the next supply of medication (as described below)
- ► Each drug on the discharge letter must have the CORRECT SOURCE of NEXT SUPPLY (Trust or GP)

Transfer to **GP**:

- ✓ Newly initiated or amended medication with GREEN status, e.g. citalopram, sertraline
- ✓ Newly initiated or amended medication with AMBER status, e.g. pregabalin, donepezil
- ✓ If prescribed for at least 3 months and stable newly initiated or amended AMBER ANTIPSYCHOTICS, e.g. olanzapine, quetiapine, or medication with AMBER SHARED CARE status, e.g. antipsychotic depot/LAIs, lithium, ensuring that appropriate documentation is completed and shared with the GP where appropriate.

Transfer to **TEWV** community team:

- ✓ If prescribed for less than 3 months or not stable newly initiated or amended AMBER ANTIPSYCHOTICS, e.g. olanzapine, quetiapine, or medication with AMBER SHARED CARE status, e.g. antipsychotic depots/LAIs, lithium
- ✓ Any medication with RED, PURPLE, BLACK or GREY status which is not suitable for transfer to GP e.g. clozapine, lurasidone, asenapine
- ✓ If suicidality or another risk requires shorter supply, consider how instalments can be supplied until CMHT can arrange prescriptions. Options listed above.

Long Acting and Depot Antipsychotic Injections:

- These are AMBER SHARED CARE (exc. olanzapine = RED) so can transfer on discharge according to the process above if >3 months treatment has been given and the dose/frequency is stable
- Details of the depot/LAI must be documented within the electronic discharge letter (EDL) and must include drug name, dose, frequency and date & site of last administration. This must be added in the "comments" section of the medication grid on EDL.
- Date and place of the next injection should be arranged & <u>communicated to the patient</u> prior to discharge
- > Prior to discharge, where the depot/LAI is to be initially transferred to a TEWV community team, the inpatient team must ensure arrangements to enable **completion of a NEW community depot card in time for the next dose** (including obtaining depot supply) and ensure any **previous depot cards are cancelled.**
 - This may be achieved by (check local arrangements):
 - In-patient team writing the new depot prescription and sending to CMHT base
 - Task allocation at discharge meeting where CMHT are present
 - E-mail to generic CMHT (or CMHT pharmacy team) mailbox (with high priority)
 - Scanning front page of drug chart (depot section) to CMHT

Title	MSS18: Safe transfer of psychotropic medication at discharge	Date of issue	20 th October 2021
Approved by	Drug & Therapeutics Committee (September 2021)	Review due	1 st October 2024